Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2014

View Archived Issues

Potent c-Ros-1 inhibitors discovered at Janssen and NovAliX

Antiangiogenic and antitumor activity described for alpha-tocopherol analogue

Gene identified as a possible novel biomarker for frontotemporal lobar degeneration

ElexoPharm and Merck & Co. report CYP11B2 inhibitors for heart failure and hypertension

U.S. institutions divulge novel GSK-3 inhibitors

Loxo Oncology initiates phase I study of Trk inhibitor for cancer

Covagen initiates first clinical trial of FynomAb bispecific inhibitor

Addition of VX-661 to Kalydeco improves lung function in phase II trial in CF

Promising preclinical results for a novel, live-attenuated plague vaccine

Ruthigen submits IND for anti-infective surgical lavage

Phase III ovarian cancer trial of vintafolide stopped due to lack of efficacy

Camicinal proves well tolerated in diabetic patients with gastroparesis

Bristol-Myers Squibb describes novel FXIa inhibitors

New macrocyclic ketoamides disclosed by Roche

Bristol-Myers Squibb updates pipeline progress of first quarter 2014

NIH gives grant to Scripps Research Institute to develop diagnostics

Cellectar Biosciences' glioma diagnostic obtains FDA orphan drug designation

diaDexus completes validation study for PLAC Test for Lp-PLA2 Activity

Advaxis' immunotherapy product to enter clinic for pediatric bone cancer

ADDF raises funding for trial investigating rasagiline for Alzheimer's disease

Pierre Fabre obtains European approval for Hemangiol

World Asthma Day: Disease control through discovery of new therapeutic targets and models

Acorda receives complete response letter from FDA for Plumiaz

FDA approves Epanova for hypertriglyceridemia

FDA approves IND for Kinex's Oratecan

Alexion achieves regular approval for Soliris in aHUS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...